Profusa Inc.
(NASDAQ:PFSA) stock fell in Monday premarket trading after the company announced leadership changes and signed a non-binding acquisition term sheet.
PFSA has lost about 99.95% of its value over the past 12 months.
Diagnostics Acquisition Term Sheet Profusa signed a non-binding term sheet to acquire a privately held, commercial-stage health diagnostics and toxicology testing company.
The proposed combination would create a publicly traded diagnostics company with national CLIA-certified laboratories and recurring revenue from providers serving addiction treatment, pain management and behavioral health.
